LIMN
Financials
- Market Capitalization 5.18 M
- Employee 1
- Founded 2020
- CEO N/A
- Website liminatuspharma.com
- Headquarter Delaware, United States
- FIGI BBG01HVYG111
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 4907 |  PMCB PharmaCyte Biotech, Inc. - Common Stock | 0.50 USD | -3.85% | -5.66% | -10.71% | -50.00% | 5.37 M USD | ||
| 4916 |  DRMA Dermata Therapeutics, Inc. - Common Stock | 1.29 USD | -3.73% | -21.34% | +8.40% | -9.79% | 5.19 M USD | ||
| 4922 |  BRTX BioRestorative Therapies, Inc. - Common Stock | 0.20 USD | 0.00% | -13.04% | -4.76% | -89.25% | 5.10 M USD | ||
| 4925 |  BTAI BioXcel Therapeutics, Inc. - Common Stock | 0.16 USD | -11.11% | -79.49% | -80.25% | -89.87% | 5.01 M USD |
Frequently asked questions about Liminatus Pharma, Inc. Class A Common Stock
What is the Liminatus Pharma, Inc. Class A Common Stock stock price today?
The current price of Liminatus Pharma, Inc. Class A Common Stock (LIMN) is 3.86. Over the past 24 hours, the stock has changed by -8.75%. Follow the LIMN chart for real-time price dynamics.
What is the stock ticker of Liminatus Pharma, Inc. Class A Common Stock?
Liminatus Pharma, Inc. Class A Common Stock trades under the ticker LIMN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Liminatus Pharma, Inc. Class A Common Stock stock going up?
LIMN has changed by -16.81% over the last week, +3409.09% over the last month, and +30.85% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Liminatus Pharma, Inc. Class A Common Stock?
Liminatus Pharma, Inc. Class A Common Stock currently has a market capitalization of 5.18 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Liminatus Pharma, Inc. Class A Common Stock earnings last quarter?
Last quarter, Liminatus Pharma, Inc. Class A Common Stock reported earnings of -1.5 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Liminatus Pharma, Inc. Class A Common Stock net income for the last quarter?
Liminatus Pharma, Inc. Class A Common Stock reported net income of -1.41 M for the last quarter. The previous quarter showed -1.12 M, which means net income changed by -25.23%.
How many employees does Liminatus Pharma, Inc. Class A Common Stock have?
As of the latest available data, Liminatus Pharma, Inc. Class A Common Stock has 1 employees. Workforce size can provide additional context about the company's scale and operations.
How can I buy Liminatus Pharma, Inc. Class A Common Stock stock?
You can buy Liminatus Pharma, Inc. Class A Common Stock (LIMN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Liminatus Pharma, Inc. Class A Common Stock stock?
Investing in Liminatus Pharma, Inc. Class A Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the LIMN chart and related analysis on metatrader.com as part of your research.